臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lin z z"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 216-240 / 330 (共14頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-05-26T09:26:19Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients	Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J.
臺大學術典藏	2020-05-25T07:35:32Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Yang C.-H.;Yang P.-C;Cheng A.-L;Chia-Chi Lin;Hsu C.-H;Yu C.-J;Chang Y.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Chang Y.-C; Yu C.-J; Hsu C.-H; Chia-Chi Lin; Cheng A.-L; Yang P.-C; Yang C.-H.
臺大學術典藏	2020-05-25T07:35:28Z	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors	Chia-Chi Lin; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; Yang C.-H; Mok T.
臺大學術典藏	2020-05-25T07:35:26Z	A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor	Yang S.-H; Chia-Chi Lin; Lin Z.-Z; Tseng Y.-L; Hong R.-L.
臺大學術典藏	2020-05-25T07:35:15Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y
臺大學術典藏	2020-05-25T07:35:05Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients	Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J.
臺大學術典藏	2020-05-25T06:52:07Z	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma	Wang Y.-C; Wang D; Hung J.-H; Tang M; Lin Z.-Z; Chen T.-J; Cheng A.-L; Chen C.-S.; Yen-Shen Lu;Kashida Y;Kulp S.K;Wang Y.-C;Wang D;Hung J.-H;Tang M;Lin Z.-Z;Chen T.-J;Cheng A.-L;Chen C.-S.; YEN-SHEN LU; Kashida Y; Kulp S.K
臺大學術典藏	2020-05-25T06:51:58Z	The impact of diabetes mellitus on prognosis of early breast cancer in Asia	Lai M.-S.;Cheng A.-L;Kuo R.N.C;Chen H.-M;Yen-Shen Lu;Lin Z.-Z;Shau W.-Y;Shao Y.-Y;Chen W.-W; Chen W.-W; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; YEN-SHEN LU; Chen H.-M; Kuo R.N.C; Cheng A.-L; Lai M.-S.
臺大學術典藏	2020-05-25T06:51:58Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L.
臺大學術典藏	2020-05-25T02:45:35Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y; Yang J.C.-H; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y; Lin Z.-Z; Lan K.-H; Cheng A.-L; Kuo S.-H.
臺大學術典藏	2020-05-25T01:32:58Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2020-05-20T05:11:42Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2020-05-20T04:46:48Z	Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status	MING-CHIN YANG; Lin Z.-Z.; Liao C.-H.; Tan E.C.-H.; Chen H.-C.; Ming-Chin Yang;Lin Z.-Z.;Liao C.-H.;Tan E.C.-H.;Chen H.-C.
臺大學術典藏	2020-04-28T07:25:39Z	Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma	Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Yeh K.-H.;Wang C.-H.;Chih-Hung Hsu;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; CHIH-HUNG HSU; Liu M.-Y.; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:30Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z.
臺大學術典藏	2020-04-28T07:25:28Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:28Z	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma	Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:27Z	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma	Shao Y.U.-Y. ;Chen P.-J. ;Lin Z.-Z. ;Huang C.-C. ;Ding Y.-H. ;Lee Y.-H. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:27Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:25Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:13Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2020-04-28T07:25:08Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2020-04-10T12:51:23Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z.
臺大學術典藏	2020-04-10T12:51:22Z	Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival	Cheng A.-L.; Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Chiun Hsu
臺大學術典藏	2020-04-10T12:51:21Z	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma	Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.

顯示項目 216-240 / 330 (共14頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52828359 線上人數 : 749 教育部委託研究計畫計畫執行:國立臺灣大學圖書館